ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjogren’s syndrome"

  • Abstract Number: 2830 • 2017 ACR/ARHP Annual Meeting

    Epigenetic Cell Counting: A Novel Tool to Quantify Immune Cells in Salivary Glands Detects Robust Correlations of T Follicular Helper Cells with Immunopathology

    Joel A.G. van Roon1, Frederique M. Moret1, Sofie L.M. Blokland1, Aike A. Kruize2, Gerben Bouma3, Andre van Maurik3, Sven Olek4, Ulrich Hoffmueller4 and Timothy R.D.J. Radstake5, 1Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Immunoinflammation TAU, GlaxoSmithKline, Stevenage, United Kingdom, 4Epiontis GmbH, Berlin, Germany, 5Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Histological analysis of salivary glands for decades has been a valuable tool in the characterization of patients with primary Sjögren’s syndrome (pSS) and non-Sjögren’s…
  • Abstract Number: 552 • 2017 ACR/ARHP Annual Meeting

    Mast Cells Are Involved in the Pathogenesis of Sjögren  Syndrome By Inducing Tissue Fibrosis

    Shinjiro Kaieda1, Kyoko Fujimoto2, Masaki Okamoto3, Masaki Tominaga2, Tomoaki Hoshino4 and Hiroaki Ida5, 1Department of Medicine, *Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, kurume, Japan, 2Kurume University School of Medicine, Kurume, Japan, 3Medicine, Kurume University School of Medicine, Kurume, Japan, 4Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, 5Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan

    Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis and…
  • Abstract Number: 873 • 2017 ACR/ARHP Annual Meeting

    Type I High-IFN Gene Signature in Associated with Higher Essdai at Enrollmment and Follow-up in the Prospective Multicenter Assess Cohort of 395 Patients

    Jacques-Eric Gottenberg1, Pierre-Etienne BOST2, Benno Schwikowski2, Raphaele Seror3, Valérie Devauchelle-Pensec4, Philippe Dieudé5, Jean-Jacques Dubost6, Anne Laure Fauchais7, Vincent Goeb8, Eric Hachulla9, Pierre Yves Hatron10, Claire Larroche11, Véronique Le-Guern12, Jacques Morel13, Aleth Perdriger14, Emmanuelle Dernis15, Stephanie Rist Bouillon16, Alain Saraux17, Damien Sène18, Jean Sibilia19, Olivier Vittecoq20, Gaetane Nocturne21, Sarah TUBIANA22, Philippe Ravaud23 and Xavier Mariette24, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Pasteur Institute, System biologique, PARIS, France, 3Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, 4Department of Rheumatology, Brest University Hospital, Brest, France, 5Rheumatology, Hôpital Bichat, Paris, France, 6Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 7Rheumatology, Limoges, France, 8Rheumatologie, Rheumatology Department CHU Teaching Hospital Amiens, Amiens, France, 9CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, 10Internal Medicine, Lille, France, 11Internal Medicine, Paris, France, 12service de médecine interne, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 13Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 14Service de Rhumatologie, CHRU de Rennes, Rennes, France, 15Service de Rhumatologie, CH du Mans, Le Mans, France, 16Rhumatologie, Hopital La Source, La Source, France, 17Rheumatology, Brest University Hospital, Brest, France, 18Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, 19Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 20INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 21INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, 22CRB Bichat, PARIS, France, 23Hôpital Hôtel Dieu, Paris, France, 24Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France

    Background/Purpose: The type I interferon (IFN) signature is a hallmark of the pathogenesis of primary Sjögren’s syndrome (pSS). However, little is known regarding the clinical…
  • Abstract Number: 1491 • 2017 ACR/ARHP Annual Meeting

    Is There a Seasonal Effect on Fatigue, Pain, and Dryness in Primary Sjögren’s Syndrome?  Data from the Prospective Assess Cohort and  from 3 Randomized Controlled Trials

    Pierre-Marie DURET1, Nicolas MEYER2, Alain Saraux3, Valérie Devauchelle-Pensec4, Jean Sibilia5, Raphaele Seror6, Véronique Le-Guern7, Claire Larroche8, Aleth Perdriger9, Xavier Mariette10 and Jacques-Eric Gottenberg11, 1Rhumatology, Hautepierre Hospital, STRASBOURG, France, 2clinical research, Hautepierre Hospital, STRASBOURG, France, 3Rheumatology, Brest University Hospital, Brest, France, 4Department of Rheumatology, Brest University Hospital, Brest, France, 5Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 6Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, 7service de médecine interne, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 8Internal Medicine, Paris, France, 9Service de Rhumatologie, CHRU de Rennes, Rennes, France, 10Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 11CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France

    Background/Purpose: A seasonal effect was reported on fatigue and pain in rheumatoid arthritis. We speculated that fall and winter could be associated with increased fatigue…
  • Abstract Number: 2873 • 2017 ACR/ARHP Annual Meeting

    DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome

    Hiroyuki Takahashi, Hiroto Tsuboi, Hiromitsu Asashima, Hanae Kudo, Yuko Ono, Saori Abe, Yuya Kondo, Isao Matsumoto and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose:Some reports on DNA microarray analysis in labial salivary glands (LSGs) of Sjögren’s syndrome (SS) and healthy controls (HCs) showed that the genes associated with…
  • Abstract Number: 553 • 2017 ACR/ARHP Annual Meeting

    Decreased Circulating CXCR3+CCR9+ Th Cells Coincides with Elevated Levels of Their Ligands CXCL10 and CCL25 in the Salivary Gland of Sjögren’s Syndrome Patients Which Synergistically Facilitate Th Cell Migration

    Sofie L.M. Blokland1,2, Maarten R. Hillen3,4, Stephan Meller5, Bernhard Homey5, Glennda Smithson6, Aike A. Kruize2, Timothy R.D.J. Radstake2,7 and Joel A.G. van Roon2,3, 1Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 4Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Department of Dermatology, University of Düsseldorf, Düsseldorf, Germany, 6Takeda Global Research & Development Center, Inc, Chicago, IL, 7Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by dryness and lymphocytic infiltration in the salivary glands. CXCR3+ T cells and ligands CXCL9/10/11 are known to…
  • Abstract Number: 874 • 2017 ACR/ARHP Annual Meeting

    Effect of Rituximab on a Salivary Gland Ultrasound Score in Primary Sjögren’s Syndrome: Results of Multicentre Double-Blind Randomised Controlled Trial Sub-Study

    Benjamin Fisher1, Colin Everett2, John Rout3, John O'Dwyer2, Paul Emery4, Costantino Pitzalis5, Wan-Fai Ng6, Andrew Carr7, Colin Pease2, Elizabeth Price8, Nurhan Sutcliffe9, Jimmy Makdissi10, Anwar Tappuni10, Nagui Gendi11, Frances Hall12, Sharon Ruddock2, Catherine Fernandez2, Claire Hulme2, Kevin Davies13, Christopher J. Edwards14, Peter Lanyon15, Robert J. Moots16, Euthalia Roussou17, Linda Sharples18, Michele Bombardieri19 and Simon Bowman20, 1Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3Birmingham Dental Hospital, Birmingham, United Kingdom, 4NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 6Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 7Newcastle Dental Hospital, Newcastle, United Kingdom, 8Great Western Hospital, Swindon, United Kingdom, 9Royal London Hospital, London, UK, London, United Kingdom, 10Barts Health NHS Trust, London, United Kingdom, 11Basildon and Thurrock University Hospital, Basildon, UK, Basildon, United Kingdom, 12School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, 13University of Sussex, Brighton, United Kingdom, 14University of Southampton, Southampton, United Kingdom, 15University of Nottingham, Nottingham, United Kingdom, 16University of Liverpool, Liverpool, United Kingdom, 17Barking Havering and Redbridge University hospitals NHS Trust, London, United Kingdom, 18London School of Hygiene and Tropical Medicine, London, United Kingdom, 19Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, 20Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom

    Background/Purpose: B lymphocytes are important in the pathogenesis of primary Sjögren’s syndrome (PSS), but two phase III trials (TEARS and TRACTISS) of the B cell…
  • Abstract Number: 1492 • 2017 ACR/ARHP Annual Meeting

    Total Body Water Correlates with Ocular Sicca Symptoms in Primary SjöGren’s Syndrome

    Gabriela Hernandez-Molina1, Paloma Almeda-Valdés2, Guadalupe López-Carrasco2, Miguel Astudillo-Angel1, Victor Zamora-Legoff3, Carlos Aguilar-Salinas4 and Ivette Cruz-Bautista5, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, 2Endocrinology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, 3Rheumatology and Immunology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico D.F., Mexico, 4Endocrinology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico D.F., Mexico, 5Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico

    Background/Purpose: Patients with primary Sjögrens’ syndrome (PSS) suffer from severe alterations in both the quality and quantity of saliva and tears. Body water represents around…
  • Abstract Number: 2874 • 2017 ACR/ARHP Annual Meeting

    Thymic Stromal Lymphopoietin (TSLP) Expression Is Associated with Lymphoproliferation and Lymphoma in Primary Sjögren’s Syndrome

    Saviana Gandolfo1, Cinzia Fabro1, Michela Bulfoni2, Sabino Russi3, Luca Quartuccio1, Domenico Ettore Sansonno3, Carla Di Loreto2, Daniela Cesselli2 and Salvatore De Vita1, 1Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, 2Institute of Anatomic Pathology, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, 3Department of Biomedical Sciences and Human Oncology, University of Bari, Italy, Bari, Italy

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune and lymphoproliferative systemic disease with B cell hyperactivity and increased risk of non-Hodgkin lymphoma (NHL) evolution. In…
  • Abstract Number: 554 • 2017 ACR/ARHP Annual Meeting

    Prognostic Significance of Double Positive Anti Ro/SS-a and La/SS-B Antibodies in Patients with Primary Sjogren’s Syndrome: Prospective Salivary Gland Ultrasound Study

    Sang Heon Lee1, Kyung-Ann Lee2 and Hae-Rim Kim3, 1Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, Republic of (South), 2Department of Nuclear medicine, Konkuk University Medical center, seoul, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea, Republic of (South)

    Background/Purpose: The aim of the study was to assess the diagnostic value of salivary gland ultrasonography (SGUS) as a single test for the detection of…
  • Abstract Number: 875 • 2017 ACR/ARHP Annual Meeting

    Serum Autoantibody Profiling of Primary Sjoegren’s Syndrome Patients Reveals Novel Biomarkers Associated with the Disease, Disease Activity, and Clinical Response to VAY736

    Petra Budde1, Julie Doucet2, Hans-Dieter Zucht1, Remi Kazma2, Paul Maguire2, Alexandre Avrameas2, Marie-Anne Valentin2, Stephen Oliver2, Peter Schulz-Knappe1 and Alessandra Vitaliti2, 1Protagen AG, Dortmund, Germany, 2Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland

    Background/Purpose: Overexpression of B cell activating factor (BAFF) in salivary glands contributes to the pathogenesis of primary Sjögren’s syndrome (pSS) by promoting autoantibody (AAB) production.…
  • Abstract Number: 1494 • 2017 ACR/ARHP Annual Meeting

    Validation of New Criteria in “The Guidance for Diagnosis of Sjögren’s Syndrome in Pediatric Patients”

    Minako Tomiita1, Ichiro Kobayashi2, Yuzaburo Inoue3, Nami Okamoto4, Naomi Iwata5, Yukiko Nonaka6, Ryoki Hara7, Hiroaki Umebayashi8, Yasuhiko Itoh9 and Masaaki Mori10, 1Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan, 2Department of Allergy and Rheumatology, Chiba Children’s Hospital, Sapporo, Japan, 3Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba, Japan, 4Pediatrics, Graduate School of Medicine, Osaka Medical College, Takatsuki, Japan, 5Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, Obu, Japan, 6Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, 7Department of Pediatrics, Yokohama City University, Graduate School of Medicine, Yokohama, Japan, 8Department of Rheumatics, Miyagi Children’s Hospital, Sendai, Japan, 9Department of Pediatrics, Nippon Medical School, Tokyo, Japan, 10Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: Sjögren’s syndrome (SS) has been thought rare during pediatric age. Because patients in this age group lack gsicca symptomsh, the diagnosis of SS is…
  • Abstract Number: 2876 • 2017 ACR/ARHP Annual Meeting

    Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome

    Tiezheng Yuan1, Michelle Petri2, Alan N. Baer3 and H. Benjamin Larman1, 1Pathology (Immunology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 3Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: An unbiased and comprehensive approach to the analysis of Sjögren’s syndrome (SS) antibody repertoires would provide important data on its pathogenesis. Phage ImmunoPrecipitation sequencing…
  • Abstract Number: 555 • 2017 ACR/ARHP Annual Meeting

    The Corrected QT(QTc) Interval Is Associated with Myocardial Fibrosis in Primary  Sjögren Syndrome, Assessed By a Cardiac Magnetic Resonance Approach: A Prospective Pilot Study at a Single Center

    Atsuma Nishiwaki1, Hitomi Kobayashi1, Isamu Yokoe2, Yosuke Nagasawa3, Kaita Sugiyama3, Natsumi Ikumi4, Takamasa Nozaki3, Noboru Kitamura5 and Masami Takei5, 1Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 2Rheumatology, Kyoundo Hospital, Sasaki Institute, Tokyo, Japan, 3Nihon University School of Medicine, Tokyo, Japan, 4St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, 5Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan

    Background/Purpose: Congenital heart block in the fetus and neonate, which can cause acquired QT prolongation, may be associated with maternal anti-SS-A/anti-SS-B autoantibodies. However, there are…
  • Abstract Number: 876 • 2017 ACR/ARHP Annual Meeting

    Epidemiologic Subsets Drive a Differentiated Clinical and Immunological Presentation of Primary Sjögren Syndrome: Analysis of 9302 Patients from the Big Data International Sjögren Cohort

    Soledad Retamozo1,2,3, Pilar Brito-Zerón3,4, Margit Zeher5, Kathy L. Sivils6, Raphaele Seror7, Thomas Mandl8, Xiaomei Li9, Chiara Baldini10, Jacques-Eric Gottenberg11, Debashish Danda12, Roberta Priori13, Luca Quartuccio14, Gabriela Hernandez-Molina15, Aike A. Kruize16, Seung-Ki Kwok17, Marie Wahren-Herlenius18, Sonja Praprotnik19, Damien Sene20, Roberto Gerli21, Roser Solans22, Yasunori Suzuki23, David A. Isenberg24, Maureen Rischmueller25, Gunnel Nordmark26, Guadalupe Fraile27, Piotr Wiland28, Hendrika Bootsma29, Takashi Nakamura30, Valeria Valim31, Roberto Giacomelli32, Valérie Devauchelle-Pensec33, Benedikt Hofauer34, Michele Bombardieri35, Virginia Fernandes Moça Trevisani36, Daniel S. Hammenfors37, Steven E. Carsons38, Sandra Gofinet Pasoto39, Jacques Morel40, Tamer Gheita41, Fabiola Atzeni42, Cristina F. Vollenweider43, Belchin Kostov44, Xavier Mariette45 and Manuel Ramos-Casals46, 1Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, 2Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, 3Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, 4Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, 5Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, 6Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, 8Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, 9Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, 10Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 11Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, 12Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, 13UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, 14Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, 15Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición SZ, mexico city, Mexico, 16Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 17[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), 18Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 19Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 20Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, 21University and Azienda Ospedaliera of Perugia, Perugia, Italy, 22Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 23Division of Rheumatology, Kanazawa University Graduate School of Medicine, Ishikawa, Japan, Kanazawa, Japan, 24Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 25Rheumatology, The Queen Elizabeth Hospital, South Australia, Adelaide, Australia, 26Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, 27Autoimmune Diseases Department, Hospital Ramón y Cajal, Madrid, Spain, 28Department and Clinic of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, 29Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 30Department of Radiology and Cancer Biology, Nagasaki University School of Dentistry, Nagasaki, Japan, 31Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, 32University of L'Aquila, L'Aquila, Italy, 33Department of Rheumatology, Brest University Hospital, Brest, France, 34Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, 35Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, 36UNIFESP, Sao Paulo, Brazil, San Paulo, Brazil, 37Department of Rheumatology, Haukeland University Hospital, University of Bergen, Bergen, Norway, 38NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, 39Internal Medicine, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 40Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, 41Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, 42Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, 43Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, 44Primary Care Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Primary Care Centre Les Corts, CAPSBE, Barcelona, Spain, 45Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 46Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain

    Background/Purpose: To analyse whether epidemiologic factors (such as gender or age at diagnosis of the disease) are associated with particular disease expressions and define some…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology